Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cryosim-1
- Development stage
- Unknown
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
Cryosim-1 is a synthetic, selective agonist of the transient receptor potential melastatin 8 (TRPM8) channel, developed as a topical treatment for pruritic skin conditions. By activating TRPM8 channels in sensory neurons, it induces a cooling sensation and inhibits itch transmission. Clinical trials have demonstrated its efficacy and safety in reducing pruritus intensity and improving sleep quality in patients with prurigo nodularis (PN), chronic urticaria, eczema, and localized scalp pruritus. The drug provides rapid relief—sometimes within 10 minutes—and its anti-pruritic effect can last over two hours after application. No significant adverse reactions have been reported in clinical studies[2][3][6][7][9].
- Brand names
- Intrinsic IB Spot
- Other names
- Cryosim-1 gelCryosim1 gelCryosim 1 gelTRPM8 agonist gelTRPM-8 agonist gelTRPM 8 agonist gel
02
Targets
TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on cryosim-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cryosim-1.